Compare SLI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | ACHV |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 618.0M |
| IPO Year | 2011 | 2018 |
| Metric | SLI | ACHV |
|---|---|---|
| Price | $2.57 | $163.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.25 | ★ $14.67 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.91 | $2.62 |
| 52 Week High | $6.40 | $8.61 |
| Indicator | SLI | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 68.63 |
| Support Level | $2.13 | $3.99 |
| Resistance Level | $2.67 | N/A |
| Average True Range (ATR) | 0.13 | 0.37 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 55.47 | 73.46 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.